US FDA Fast Tracks Antithrombotic from BMS and J&J

Johnson & Johnson and Bristol Meyer’s Squibb’s (BMS’s) antithrombotic milvexian has been fast tracked by the US Food and Drug Administration for three indications, according to the companies. The drug received the designation for the drug for stroke, atrial fibrillation, and acute coronary syndrome. Fast track designation is often granted for drugs that address medical conditions with limited treatment options.

According to J&J’s James List, “For milvexian to receive fast track designation from the FDA for all three indications demonstrates the enormous unmet need that still exists for the treatment of thrombotic events, like heart attack and stroke.”

To read more, click here.

(Source: PM Live, May 26^th, 2023)